Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia

Affiliations

• ¹ Department of Pediatric Hematology/Oncology and of Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Rome, Sapienza University of Rome, Rome, Italy. [email protected].
• ² The Hospital for Sick Children/University of Toronto, Toronto, ON, Canada.
• ³ St. Anna Children's Hospital, Vienna, Austria.
• ⁴ Department of Paediatric Oncology/Hematology/BMT, Charité Universitäts Medizin Berlin, Berlin, Germany.
• ⁵ Amgen Inc, Thousand Oaks, CA, USA.
• ⁶ Nationwide Children's Hospital, The Ohio State University, Columbus, OH, USA.
• ⁷ Cook Children's Medical Center, Fort Worth, TX, USA.
• ⁸ Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.
• ⁹ Children's Hospital Los Angeles and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
• ¹⁰ Primary Children's Hospital, Pediatric Hematology/Oncology, University of Utah, Salt Lake City, UT, USA.
• ¹¹ Department of Pediatric Hematology/Oncology and of Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Rome, Sapienza University of Rome, Rome, Italy.
• ¹² Center for Clinical and Translational Research, Seattle Children's Hospital and Research Institute, Seattle, WA, USA.
• ¹³ Department of Pediatrics, University of Washington, Seattle, WA, USA.
• ¹⁴ Amgen Research, Munich, Germany.
• ¹⁵ City of Hope National Medical Center, Pediatric Hematology Oncology, Duarte, CA, USA.
• ¹⁶ Janssen Pharmaceutica, Beerse, Belgium.